Krithika Rajagopalan, PhD

Research Reports

Health Care Use and Costs Among Medicare Patients With Chronic Obstructive Pulmonary Disease Treated With Short-Acting Beta Agonists or Long-Acting Beta Agonists

04/11/2016

Vamsi K. Bollu , PhD, MBA;

Flavia Ejzykowicz , PhD;

Joel W. Hay , PhD;

Krithika Rajagopalan , PhD;

Abstract: Chronic obstructive pulmonary disease (COPD) has a high prevalence among older adults and is the third leading cause of mortality in the United States. COPD exacerbations can require hospitalizations,...

...

04/11/2016

Journal of Clinical Pathways

Research Reports

Length of Stay and Costs of COPD: Analysis of Hospitalized Patients Treated With Arformoterol or Nebulized Short-Acting Beta2-Agonists

04/11/2017

Tina Hunter , PhD;

Scott B. Robinson , PhD, MD;

Vamsi K. Bollu , PhD, MBA;

Krithika Rajagopalan , PhD;

Bernadette H. Johnson , MBA;

Frank R. Ernst , PharmD, MS;

Abstract: Hospitalization costs are substantial in chronic obstructive pulmonary disease (COPD). Little is known regarding the effect of long-acting beta2-agonists (LABAs) vs short-acting beta2-agonists (SABAs) on...

...

04/11/2017

Journal of Clinical Pathways

Real-world Persistency Outcomes associated with Pimavanserin vs other-AAPs for Parkinson’s Disease Psychosis: Analysis of Medicare Beneficiaries from 100% Sample

Abstract: OBJECTIVES: Treatment persistence (i.e., measure of real-world treatment utilization relative to patient preference) with pimavanserin (PIM), the only FDA approved atypical anti...

Krithika Rajagopalan , PhD;

01/19/2023